<DOC>
	<DOCNO>NCT01237197</DOCNO>
	<brief_summary>Extreme pediatric obesity , fast grow category obesity youth , associate high risk develop cardiovascular disease ( CVD ) type 2 diabetes ( T2DM ) . Obesity track strongly adulthood intervention early life may reduce risk develop cardiovascular disease type 2 diabetes . Few drug therapy weight loss evaluate adolescent . Since exenatide associate weight loss improve risk factor cardiovascular disease type 2 diabetes adult , may useful extremely obese youth . Our primary objective study generate preliminary data ability exenatide reduce body mass index ( BMI ) improve risk factor cardiovascular disease type 2 diabetes 26 extremely obese adolescent ( age 12-19 year ) three-month , randomize , double-blind , placebo-controlled pilot clinical trial . GLP-1 therapy never evaluate treatment pediatric obesity innovative approach challenge significant health care problem .</brief_summary>
	<brief_title>Exenatide Extreme Pediatric Obesity</brief_title>
	<detailed_description>26 ( approximately 13 per site ) extremely obese ( Body mass index [ BMI ] &gt; = 1.2 time 95th percentile BMI &gt; = 35 kg/m2 ) adolescent ( age 12-19 year old ) enrol six-month study consist three-month , randomize , double-blind ( participant investigator ) , placebo-controlled pilot clinical trial phase follow three-month open-label extension participant receive exenatide . For initial three-month phase , participant equally ( site ) randomly assign one two group : 1 ) exenatide plus lifestyle modification , 2 ) placebo plus lifestyle modification . Following baseline test , subject randomly assign study group . Participants return one-month titration assessment safety ( blood draw adverse event assessment ) injection/lifestyle modification compliance three-months reassessment baseline variable injection/lifestyle modification compliance allocation study drug three-month open-label extension . Participants return four-months assessment safety ( blood draw adverse event assessment ) injection/lifestyle modification compliance six-months reassessment baseline variable injection/lifestyle modification compliance . All subject , regardless group assignment , participate clinical lifestyle modification program offer either University Minnesota Children 's Hospitals Clinics weight management program . Participants family receive regular ( approximately bi-monthly ) face-to-face and/or phone behavioral- , dietary- , physical activity-counseling multi-disciplinary team health care professional include physician , dietician , register nurse , psychologist , exercise physiologist . Screening include review medical record previous clinical laboratory data . The following measure collect baseline , 3 month , 6 month . Subject ask fast minimum 12 hour .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Pediatric Obesity</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Body mass index &gt; = 1.2 time 95th percentile ( base gender age ) Body mass index &gt; = 35 kg/m2 1219 year old Type 1 2 diabetes mellitus Previous ( within 3months ) current use weight loss medication ( patient may undergo washout ) Previous bariatric surgery Recent initiation ( within 1month ) antihypertensive lipid medication Previous ( within 1month ) current use medication treat insulin resistance hyperglycemia ( patient may undergo washout ) Major psychiatric disorder Pregnant planning become pregnant Tobacco use Liver/renal dysfunction History pancreatitis Obesity associate genetic disorder Hyperthyroidism uncontrolled hypothyroidism Uncontrolled hypertriglyceridemia ( =300 mg/dL ) Current eat disorder Previous ( within 3months ) current use drug associate weight gain ( e.g . steroids/antipsychotics )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>